Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients

Abstract

Aim: The aim of the present retrospective study was to investigate the influence of neoadjuvant chemotherapy on liver regeneration after portal vein occlusion before major hepatectomy.

Method: Between 2003 and 2007, 26 patients underwent portal vein occlusion, of whom 22 had portal vein embolisation and 4 portal vein ligation. 15 of 23 patients with colorectal liver metastases had neoadjuvant chemotherapy.

Results: After portal vein occlusion, the ratio of the future liver remnant volume to total parenchymal liver volume (FLR%) was reduced in patients receiving neoadjuvant chemotherapy (27 +/- 1% vs 32 +/- 1%, p = 0.03). A smaller future liver remnant before portal vein occlusion resulted in a greater degree of hypertrophy (r(2) = 0.18, p = 0.04). Patients with tumour size greater than 60 mm showed a decreased degree of hypertrophy (7 +/- 1)% as compared to patients with smaller tumours (13 +/- 1%, p = 0.01). There was one death shortly after portal vein embolisation. 19/26 patients were resected with zero operative mortality.

Conclusion: Prolonged neoadjuvant chemotherapy has a small negative effect on liver regeneration induced by portal vein occlusion. Liver regeneration induced by portal vein occlusion is relatively large when tumour burden is small.